http___medlib.mef.hr_992__2.xml
1.1 1.2 2.1 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4.1
Popović, Alek and Demirović, Alma and Spajić, Borislav and Štimac, Goran and Krušlin, Božo and Tomas, Davor (2010) Expression and prognostic role of syndecan-2 in prostate cancer. Prostate Cancer and Prostatic Diseases, 13 (1). English abstract Syndecans are a four-member family of transmembrane heparan sulphate proteoglycans that have different functions in cell signalling, adhesion, cytoskeleton organization, migration, proliferation, and angiogenesis. Several studies investigated the role of syndecan-2 (SDC2) in different carcinomas; however, only one being focused on SDC2 in prostate cancer. SDC2 expression and relationship with established prognostic features were assessed in a cohort of 86 patients treated with radical prostatectomy for clinically localized prostate adenocarcinoma. SDC2 expression was present in the majority of prostate cancers and absent in only 11.6% of cases. SDC2 expression was also recorded in cells of prostatic intraepithelial neoplasia, whereas normal prostatic epithelial tissue and stroma did not express SDC2. SDC2 overexpression in prostate cancer was significantly associated with established features indicative of worse prognosis such as higher preoperative PSA (P=0.011), higher Gleason score (P<0.001), positive surgical margins (P<0.003), and extraprostatic extension of disease (P<0.003). Moreover, expression of SDC2 was also associated with biochemical disease progression on univariate analysis (P<0.001). Study results supported the potential role of SDC2 in prostatic carcinogenesis and cancer progression. Moreover, SDC2 could serve as an additional prognostic marker that might help in further stratifying the risk of disease progression in patients with prostate cancer. Actions (login required)
1.1 1.2 2.1 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 4.1 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 5.10 5.11 5.12 5.13 5.14 5.15 5.16 5.17 6.1 7.1 8.1
Popović, Alek (2011) Prognostička vrijednost izraženosti sindekana-1 i sindekana-2 u adenokarcinomu prostate [Prognostic value of syndecan-1 and syndecan-2 in prostatic adenocarcinoma]. PhD thesis, Sveučilište u Zagrebu. Abstract In this study, we analyzed the expression and prognostic value of syndecan-1 and-2 in prostate cancer. Hypothesis of this study was that the increased expression of syndecan-1 and 2 in prostate cancer is associated with poorer disease prognosis. The study included 86 patients and examined marker expression were analyzed immunohistochemistry with monoclonal antibodies to syndecan-1 and-2. Syndecan-1 was over-expressed in cancer and benign prostatic tissue while syndecan-2 was expressed only in prostate cancer. Patients with excessive expression of syindecan-1 and 2 in prostatic cancer had significantly higher preoperative PSA, postoperative Gleason score greater and shorter survival time without recurrence (p <0.05). Finally, they also had higher stage of disease (p <0.05). Kaplan-Meier analysis showed that patients with excessive expression of syindecan-1 (p <0,001) and syndecan-2 (p <0,001) were short lived without recurrence compared with patients in whom there was no record of excessive expression of studied markers. In Cox regression analysis as statistically significant factors for the length of survival without recurrence showed a preoperative PSA (p = 0.013), disease stage (TNM) (p <0,001) and over-expression of syndecan-1 (p=0.038). Based on the results we can conclude that syndecan-1 that is expressed in benign prostatic tissue may play a role in the progression of cancer while syndecan-2, which appears only in the cancer could have a role in the development of prostate cancer. Syndecan-1 and-2 were significantly associated with recognized prognostic factors, and their prognostic value was confirmed in univariate and in multivariate analysis. Abstract in Croatian U ovom istraživanju analizirana je izraženost i prognostička vrijednost sindekana-1 i sindekana-2 u karcinomu prostate, a hipoteza istraživanja je bila da je povećana izraženost sindekana-1 i 2 u karcinomu prostate povezana sa lošijom prognozom bolesti. Na temelju postavljene hipoteze određeni su sljedeći ciljevi istraživanja: 1. Imunohistokemijski odrediti izraženost sindekana-1 i sndekana-2 u adenikarcinomu prostate. 2. Usporediti imunohistokemijsku izraženost sindekana-1 i sindekana-2 u adenokarcinomu prostate s priznatim prognostičkim čimbenicima (preoperativni PSA, Gleason zbroj, TNM i vrijeme biokemijskog povrata bolesti). 3. Odrediti da li postoji povezanost između izraženosti sindekana-1 i sindekana-2 u adenokarcinomu prostate. 4. Odrediti koji od dva ispitivana biljega ima veću prognostičku vrijednost u adenokarcinomu prostate. U istraživanje je uključeno 86 bolesnika kojima je napravljena radikalna prostatektomija radi klinički lokaliziranog karcinoma prostate. Materijal je obrađen standardnom histološkom metodom, a dodatni rezovi tkiva koji su uz karcinom prostate sadržavali i tkivo prostate bez tumora analizirani su imunohistokemijski monoklonalnim protutijelima na sindecan-1 i sindecan-2. Sindekan-1 je bio prekomjerno izražen u karcinomu i u benignom tkivu prostate dok je sindekan-2 bio izražen samo u karcinomu prostate. Bolesnici kod kojih je nađena prekomjerna izraženost sindekana-1 i 2 u karcinomu imali su značajno veći preoperativni PSA, veći postoperativni Gleason zbroj i kraće vrijeme preživljenja bez povrata bolesti (Mann-Whitney U test, p<0.05) te viši stadij bolesti (x2 test, p<0.05). Spearmanovim faktorom korelacije nađena je pozitivna povezanost između stupnja izraženosti sindekana-1 i stupnja izraženosti sindekana-2 u karcinomu prostate (koeficijent korelacije 0.823, p<0.01). Kaplan-Meier analiza pokazala je da su bolesnici s prekomjernom izraženošću sindekana-1 (p<0.001) i sindekana-2 (p<0.001) živjeli su kraće bez povrata bolesti u usporedbi s bolesnicima kod kojih nije zabilježena prekomjeran izraženost istraživanih biljega. U Coxovoj regresijskoj analizi kao statistički značajni faktori za dužinu preživljenja bez povrata bolesti pokazali su se preoperativni PSA (p=0.013), stadij bolesti (TNM) (p<0.001) i prekomjerna izraženost sindekana-1 (p=0.038). Na temelju dobivenih rezultata može se zaključiti da bi sindekan-1 koji je izražen i u benignom tkivu prostate mogao imati ulogu u progresiji karcinoma dok bi sindekan-2 koji se pojavljuje samo u karcinomu mogao imati ulogu u nastanku karcinoma prostate. Sindekan-1 i sindekan-2 su značajno povezani s priznatim prognostičkim čimbenicima što ukazuje na njihovu pronostičku vrijednost koja je u slučaju sindekana-1 potvrđena univarijantnom i multivarijantnom analizom, a u slučaju sindekana-2 univarijantnom analizom. S obzirom na njihovu moguću ulogu u nastanku i razvoju karcinoma prostate oba ispitivana biljega su kandidati za razvoj i primjenu specifične molekularne terapije koja bi mogla olakšati i unaprijediti liječenje karcinoma prostate. Korištenjem sindekana-1 i sindekana-2 u prognostičke svrhe također bi se moglo na relativno jednostavan i jeftin način izdvojiti bolesnike kojima bi se nakon kirurške trebala uvesti i dodatna terapija koja bi spriječila povrat bolesti odnosno produžila i poboljšala kvalitetu života. Actions (login required) Downloads Downloads per month over past year